Respiratorius
1.64 SEK
-5.22 %
Less than 1K followers
RESP
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-5.22 %
+0.93 %
-7.10 %
-33.27 %
-75.88 %
-75.96 %
-96.86 %
-99.11 %
-88.57 %
Respiratorius is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. The company was established in 1999 as a spin-off from Lund University. The operations are located in Sweden, where research is conducted in-house, but also through international partners. The company has its headquarters in Lund.
Read moreMarket cap
12.92M SEK
Turnover
46.3K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
10.2
2026
Annual report '25
All
Press releases
ShowingAll content types
Respiratorius has conducted a pre-IND meeting with the FDA
Respiratorius Granted Pre-IND Meeting with FDA for VAL001
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools